Cited by 384Neuropeptides and Animal PhysiologyNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.

Devine, D P, Leone, P, Pocock, D, Wise, R A·1993·The Journal of Pharmacology and Experimental Therapeutics

Abstract

In vivo microdialysis was used to assess the involvement of ventral tegmental area (VTA) mu, delta, and kappa opioid receptors in modulation of basal extracellular ventral striatal dopamine (DA) and DA-metabolite concentrations. Independent groups of chloral hydrate-anesthetized rats were given VTA microinjections of selective opioid agonists, and extracellular ventral striatal DA and DA-metabolite concentrations were assayed using HPLC. VTA microinjections of [D-Ala2, N-Me-Phe4-Gly5-ol]-enkephalin (DAMGO; a mu agonist) and [D-Pen2, D-Pen5]-enkephalin (DDDPE; a delta agonist) each caused dose-orderly increases in ventral striatal DA and DA-metabolite concentrations. The effective concentrations of DPDPE were 100- to 1000-fold higher than the effective concentrations of DAMGO. VTA microinjections of (trans-(dl)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclo-hexyl]- benzeneacetamide) methane sulfonate hydrate (U-50,488H); a kappa agonist) failed to alter ventral striatal DA concentrations at any dose tested, but subsequent systemic injections significantly decreased DA and DA-metabolite concentrations. Pretreatment with VTA microinjections of 17-cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'- indolmorphinan hydrochloride (naltrindole; a delta antagonist) (delta antagonist) antagonized VTA DPDPE-mediated increases in ventral striatal DA and DA-metabolite concentrations but failed to antagonize VTA DAMGO-mediated increases. Pretreatment with D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP; a mu antagonist) antagonized VTA DAMGO-mediated increases but failed to antagonize VTA DPDPE-mediated increases. Thus both mu and delta receptor agonist appear capable of increasing ventral striatal DA and DA-metabolite concentrations through selective actions on their preferred class of opioid receptors in the VTA. The increases in ventral striatal DA and DA-metabolite concentrations that are seen after systemic treatment with kappa opioid agonists appear not to involve VTA opioid receptors.

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)39324-9

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dynorphins decrease and enkephalins increase the release of DA.

    “In particular, dynorphins decrease and enkephalins increase the release of DA (Devine et al. 1993; Di Chiara & Imperato 1988; Longoni et al. 1991; Pentney & Gratton 1991; Spanagel et al. 1990a,b, 1992).”

    From Reward, addiction, withdrawal to nicotine (2011) · cites this paper as Devine et al. 1993

  • The correlation of one OPRM1 SNP and DRD2 variation with community integration may reflect known interactions between the dopamine and endorphin systems in both humans and rodents, whereby endorphin activation may itself trigger a dopamine response.

    “may reflect known interactions between the dopamine and endorphin systems in both humans and rodents (40, 55, 56), whereby endorphin activation may itself trigger a dopamine response”

Cites

Still being checked.

Cited by

Sorted by citations

Authors
Devine, D. P., Leone, P., Pocock, D., & Wise, R. A.
Affiliations
Concordia University (CA)
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
1993-07
Volume
266
Issue
3
Pages
1236-1246
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2108098398
Cited by
382
References
0
Citations by year
2026: 7 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 5 · 2017: 10 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 13 · 2012: 10
FWCI
3.37
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed
Funders
National Institute on Drug Abuse (DA1720)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
ventral tegmental area, mu-opioid receptor, delta opioid receptor, kappa opioid receptor, dopamine release, ventral striatum, dopamine metabolites, DAMGO, DPDPE, U50,488H, naltrindole, CTOP, mesolimbic dopamine system, opioid receptor selectivity, enkephalin, opioid agonists, opioid antagonists
MeSH terms
Amino Acid Sequence, Analgesics, Animals, Chromatography, High Pressure Liquid, Corpus Striatum, Dialysis, Dopamine, Enkephalins, Homovanillic Acid, Hydroxyindoleacetic Acid, Limbic System, Male, Microinjections, Molecular Sequence Data, Naltrexone, Narcotic Antagonists, Pyrrolidines, Rats, Inbred Strains, Receptors, Opioid, Tegmentum Mesencephali, 3,4-Dihydroxyphenylacetic Acid, 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Enkephalin, D-Penicillamine (2,5)-, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review